scPharmaceuticals announced non-dilutive financings totaling up to $125M with funds managed by Perceptive Advisors, a life-sciences focused investor. Proceeds from the transactions will be used to repay existing debt, as well as to fund activities related to the ongoing commercialization of FUROSCIX, the company’s proprietary formulation of furosemide indicated for the treatment of congestion due to fluid overload in adult patients, including patients with New York Heart Association Class IV chronic heart failure.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SCPH:
- scPharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
- scPharmaceuticals Announces Positive Topline Study Results for SCP-111 (Furosemide 80 mg/1 mL) Autoinjector
- Scpharmaceuticals (SCPH) Q2 Earnings Cheat Sheet
- scPharmaceuticals files sNDA seeking to expand FUROSCIX indication